The application of technology in the fields of medicines and living sciences

the application of technology in the fields of medicines and living sciences

There are some fascinating possibilities for using nanotechnology in medicine. Some techniques are only imagined, while others are being tested at different stages.

The nanotechnology field of medicine includes applications of currently-developed nanoparticles and longer-range work involving the use of engineered nano-robots to repair cellularly (sometimes called nanomedicine).

Regardless of what you call nanotechnology, it can revolutionize the manner in which we diagnose and treat human corporal and disease damage in the future, and many technologies only imagined a few years ago, are making significant progress towards becoming reality.

A report on the opportunities offered by nanobiotechnology was published by the German pharmaceutical group, VFA.

The report found that Germany holds a strong position with 1,100 companies in space, including nanobiotechnology, the application of technology in the fields of medicines and living sciences, in the area of nanotechnology.

“The relatively young research field has the potential to further improve diagnostic and therapeutic chances for diseases which had not or can not have previously been treated sufficiently” Currently used in medical and pharmaceutical nanobiotechnological methods include high-data screening to seek new targets structures and substances, alongside the use of nanotechnology

Many nano-cancer therapies as medical devices for the treatment of brain and liver tumors have also been approved since 2010. Many other nano-based life science technologies are currently being developed in different stages.

The VFA supports a rise in nanobiotechnology technical leadership, exploiting the potential of nanomedicine and actively promoting nanomedicine, believing that this is a major advantage for patients.

“The still very recent field of research can further enhance the diagnostic and therapeutic prospects for previously incurable or not adequately treatable diseases,” explains a concluding statement from the VFA’s view of this topic.

“Public discussion will continue to highlight the huge opportunities provided by nanobiotechnology and nanobiotechnology applications that patients already can gain from today,” the statement says.

“The overall aim must be to consider and overcome concerns about this new technology on a large societal basis.”